Welcome to our dedicated page for Immunogen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on Immunogen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunogen's position in the market.
ImmunoGen, a leader in antibody-drug conjugates for cancer treatment, announced the grant of non-qualified stock options for 8,400 shares to a new employee on September 30, 2020, under its Inducement Equity Incentive Plan. This award, made in compliance with Nasdaq Listing Rule 5635(c)(4), has an exercise price of $3.60 per share, matching the company's closing stock price on that date. The options will vest over four years, incentivizing long-term employment. ImmunoGen is committed to developing targeted therapies to improve cancer patient outcomes.